Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Interview with the Innovators
PET/CT Imaging in Prostate Cancer Patients
2022
2021
2020
Relapsed/Refractory Follicular Lymphoma
PET/CT Imaging in Prostate Cancer Patients
NTRK
Gene Fusions
Ovarian Cancer Series
PET/CT Imaging in Prostate Cancer Patients
This video interview series features Neal Shore, MD, and Stephen Rowe, MD, PhD, who share their expert insights and perspectives on innovation in the imaging of patients with prostate cancer and the identification of metastases. Topics covered include recent advances in PSMA-directed imaging, the advantages of PET imaging, and the fusion of PET/CT or PET/MRI techniques. In addition, they also discuss the OSPREY and CONDOR clinical studies that led to the approval of PYLARIFY® (piflufolastat F 18) by the FDA in May 2021.
PET/CT Imaging in Prostate Cancer Patients
Insights into the Prostate Cancer Imaging Landscape
By
Steven Rowe, MD, PhD
Interview with the Innovators
Dr Steven Rowe shares insights into the prostate cancer imaging landscape and the logistics involved with different radiotracers, with particular emphasis on PYLARIFY
®
(piflufolastat F 18).
Read More ›
PET/CT Imaging in Prostate Cancer Patients
Results from the OSPREY Trial in Pre-Prostatectomy Patients
By
Steven Rowe, MD, PhD
Interview with the Innovators
Dr Steven Rowe continues his discussion of PYLARIFY
®
(piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
PYLARIFY Imaging in High-Risk Prostate Cancer
By
Steven Rowe, MD, PhD
Interview with the Innovators
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY
®
(piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
Overview of the Molecular Characteristics of PYLARIFY
By
Steven Rowe, MD, PhD
Interview with the Innovators
Dr Steven Rowe details the molecular characteristics of PYLARIFY® (piflufolastat F 18) and the OSPREY and CONDOR pivotal trials, which led to the FDA approval of PYLARIFY®.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
The Importance of Accurate Staging in Prostate Cancer
By
Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
Use of PYLARIFY® in Specific Patient Groups
By
Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
PSMA PET Imaging in Patients with Oligometastatic Prostate Cancer
Interview with the Innovators
Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
PYLARIFY and Next-Generation Imaging
By
Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
PSMA-Targeted Imaging for Prostate Cancer Treatment
By
Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment.
Read More ›
PET/CT Imaging in Prostate Cancer Patients
Overview of Current Imaging Modalities in Prostate Cancer
By
Neal Shore, MD, FACS
Interview with the Innovators
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY
®
(piflufolastat F 18).
Read More ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Out Models Cost Patients and Employers More Than They Disclose
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
By
Marianne Davies, DNP, ACNP, AOCNP, FAAN
;
Shawn Perkins, RN, BSN, OCN
3.
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma
By
William King
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes